195 related articles for article (PubMed ID: 2813190)
1. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker".
Abrahamsson PA; Falkmer S; Fält K; Grimelius L
Pathol Res Pract; 1989 Sep; 185(3):373-80. PubMed ID: 2813190
[TBL] [Abstract][Full Text] [Related]
2. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma.
Grobholz R; Bohrer MH; Siegsmund M; Jünemann KP; Bleyl U; Woenckhaus M
Pathol Res Pract; 2000; 196(5):277-84. PubMed ID: 10834383
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
[TBL] [Abstract][Full Text] [Related]
4. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.
Fixemer T; Remberger K; Bonkhoff H
Prostate; 2002 Oct; 53(2):118-23. PubMed ID: 12242726
[TBL] [Abstract][Full Text] [Related]
6. Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate.
Van de Voorde WM; Van Poppel HP; Verbeken EK; Oyen RH; Baert LV; Lauweryns JM
Mod Pathol; 1995 Aug; 8(6):591-8. PubMed ID: 8532689
[TBL] [Abstract][Full Text] [Related]
7. Correlation between histopathological form and the degree of neuroendocrine differentiations in prostate cancer.
Bocan EV; Mederle O; Sârb S; Minciu R; Agapie D; Raica M
Rom J Morphol Embryol; 2011; 52(4):1215-8. PubMed ID: 22203925
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study.
Hirano D; Jike T; Okada Y; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Yoshida T; Takimoto Y
Ultrastruct Pathol; 2005; 29(5):367-75. PubMed ID: 16257863
[TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas].
Bohrer MH; Schmoll J
Verh Dtsch Ges Pathol; 1993; 77():107-10. PubMed ID: 7511265
[TBL] [Abstract][Full Text] [Related]
10. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
[TBL] [Abstract][Full Text] [Related]
11. Divergent neuroendocrine differentiation in prostatic carcinoma.
di Sant' Agnese PA
Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study.
Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE
J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133
[TBL] [Abstract][Full Text] [Related]
13. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
[TBL] [Abstract][Full Text] [Related]
16. Receptors for BPH growth factors are located in some neuroendocrine cells.
Iwamura M; Koshiba K; Cockett AT
Prostate Suppl; 1998; 8():14-7. PubMed ID: 9690658
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
18. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
19. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
Cohen RJ; Glezerson G; Haffejee Z
Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]